Journal
JOURNAL OF CHROMATOGRAPHY B
Volume 754, Issue 1, Pages 85-90Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/S0378-4347(00)00592-2
Keywords
nordihydroguaiaretic acid
Funding
- FIC NIH HHS [401TW00316] Funding Source: Medline
Ask authors/readers for more resources
Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model. Despite these findings, there have been no reports on the pharmacokinetics of NDGA. A reverse-phase high-performance liquid chromatography (HPLC) method was developed to detect NDGA in mouse plasma. The limit of detection of this method was 0.5 mug/ml. Administration of NDGA (50 mg/kg, i.v.) to mice resulted in a peak plasma concentration of 14.7 mug/ml. The terminal half-life of NDGA was 135.0 min with a clearance of 201.9 ml/min.kg. (C) 2001 Elsevier Science B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available